NeuroThera Labs Inc., a clinical-stage biotech company and majority-owned subsidiary of SciSparc Ltd., announced that its collaboration with Clearmind Medicine Inc. has resulted in a patent application filed with the Intellectual Property Department in Hong Kong, China. The application covers an innovative combination therapy designed to treat major depressive disorder.
The therapy combines Clearmind's proprietary compound 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) sourced by NeuroThera. This MEAI-PEA synergy is positioned as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally according to World Health Organization data. Given its anticipated mechanism of action, this therapy could provide a more accessible, safer, and affordable alternative to existing antidepressants, including Selective Serotonin Reuptake Inhibitors and other conventional options.
The patent filing represents progress in developing novel therapeutics for central nervous system disorders through collaborative innovation. Clearmind, a clinical-stage neuroplastogens pharmaceutical biotech company focused on psychedelic-derived therapeutics, maintains an intellectual portfolio currently consisting of nineteen patent families. Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND," and further information is available at https://www.clearmindmedicine.com.
Forward-looking statements in the announcement emphasize the potential therapeutic benefits of the MEAI-PEA combination and its possible advantages over existing treatments. However, these statements are not guarantees of future performance and involve known and unknown risks and uncertainties. These include the early stage of development of the combination, uncertainty of preclinical and clinical outcomes, risks that the therapy may not demonstrate anticipated advantages, and risks that the patent application may not result in adequate protection. Additional risks involve regulatory approvals, intellectual property protection, capital requirements, and general business uncertainties detailed in the Company's public filings available on https://www.sedarplus.ca.
The collaboration between NeuroThera and Clearmind highlights ongoing efforts to address the significant global burden of depression through innovative pharmaceutical approaches. As major depressive disorder continues to affect millions worldwide, the development of alternative treatments with potentially improved safety and accessibility profiles represents an important advancement in mental healthcare. The progress toward patent protection for this combination therapy marks a step in the lengthy process of bringing new treatment options to market, with implications for patients, healthcare systems, and the pharmaceutical industry's approach to neuropsychiatric conditions.
